TNF and autoimmune hepatitis: Furthermore, studies aimed at treating IBD as the main disease did not allow the evaluation of the real benefit of using anti-TNF agents for AIH.[11] The weak level of evidence and increased risk of infection, especially in patients with cirrhosis, do not justify the use of anti-TNF agents as a second-line treatment in this specific population.